Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Liver Cancer · 20.12.2024 · 14 (1) · 1-7
DOI: 10.1159/000543245 ↗Kurz gefasst
Editorial in der Zeitschrift Liver Cancer, online erschienen am 20.12.2024. Verfasst von Masatoshi Kudo. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Higashi-osaka, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Higashi-osaka, Japan.
Zitieren
APA
Kudo, M. (2024). Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 14(1), 1-7. https://doi.org/10.1159/000543245
Vancouver
Kudo M. Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2024;14(1):1-7. doi:10.1159/000543245
BibTeX
@article{Kudo2024,
author = {Kudo, Masatoshi},
title = {Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma},
journal = {Liver Cancer},
year = {2024},
volume = {14},
number = {1},
pages = {1--7},
doi = {10.1159/000543245}
}
EUVIMED